- Home
- PVLA vs HTFL Comparison
PVLA vs HTFL Comparison
Compare PVLA & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVLA | HTFL |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PVLA | HTFL |
|---|---|---|
| Price | $130.71 | $50.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $228.93 | $46.00 |
| AVG Volume (30 Days) | 191.6K | ★ 1.5M |
| Earning Date | 11-10-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 52.62 | ★ 82.37 |
| EPS | N/A | ★ N/A |
| Revenue | $42,810,000.00 | ★ $176,034,000.00 |
| Revenue This Year | N/A | $41.33 |
| Revenue Next Year | N/A | $24.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.28 | 39.92 |
| 52 Week Low | $68.96 | $20.13 |
| 52 Week High | $161.38 | $54.32 |
Technical Indicators
Market Signals| Indicator | PVLA | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 55.99 |
| Support Level | $109.68 | $46.44 |
| Resistance Level | $135.23 | $51.73 |
| Average True Range (ATR) | 7.07 | 2.38 |
| MACD | -0.56 | -0.33 |
| Stochastic Oscillator | 21.32 | 48.98 |
Price Performance
Historical ComparisonAbout PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.